| November 4th | November 11th | November 18th | November 25th | |
| BIOSYS | | | | |
| MEDLINE | | | | |
1. Barnaby, J W J; Styles, A R; Cockerell, C J.
Actinic keratoses: Differential diagnosis and treatment.
Drugs & Aging, v.11, n.3, (1997): 186-205.
1. Friedman EJ; Orth CR; Brewton KA; Ponniah S; Alexander RB.
Cryosurgical ablation of the normal ventral prostate plus adjuvant does
not protect Copenhagen rats from Dunning prostatic adenocarcinoma
challenge.
Journal of Urology, 1997 Oct, 158(4):1585-8.
(UI: 97445890)
Abstract: PURPOSE: We wished to determine if cryosurgical ablation of the
normal ventral prostate of Copenhagen rats confers protective immunity
against a subsequent challenge with Dunning R3327 MatLyLu prostatic
adenocarcinoma. In human melanoma, tumor antigens have been characterized
as normal cellular proteins. We reasoned that cryosurgical ablation of the
normal prostate along with immunostimulatory adjuvants might release
prostatic antigens to the immune system engendering an immune response and
rendering rats immune to prostatic cancer cells. MATERIALS AND METHODS: On
day 0, Copenhagen rats underwent cryosurgical ablation of the normal
ventral prostate, cryosurgery and intraprostatic injection of Complete
Freund's Adjuvant (CFA), CFA injection alone, or laparotomy alone. On day
21, animals received a subcutaneous challenge of MatLyLu tumor cells. Tumor
dimensions were recorded at regular intervals by a single blinded
investigator. RESULTS: Animals receiving cryosurgical ablation of the
normal ventral prostate or intraprostatic CFA developed tumors more
frequently than animals receiving laparotomy alone and the effect was
statistically significant if animals received both cryosurgical ablation of
the prostate and intraprostatic CFA (3 experiments, 1 x 10(4) MatLyLu
cells), total number with tumors/total number challenged: laparotomy alone
3/17, cryosurgical ablation 7/17, cryosurgery plus CFA 10/16 (p = 0.013
versus laparotomy, Fisher's exact test), CFA alone 9/17. CONCLUSIONS:
Cryosurgical ablation of the normal rat ventral prostate and intraprostatic
CFA does not protect against and can enhance the tumorigenicity of MatLyLu
prostatic cancer cells at distant sites. This could be occurring through
specific immunologic effects or non-specific mechanisms induced by
cryosurgery and CFA.
2. Porter MP; Ahaghotu CA; Loening SA; See WA.
Disease-free and overall survival after cryosurgical monotherapy for
clinical stages B and C carcinoma of the prostate: a 20-year followup [see
comments].
Journal of Urology, 1997 Oct, 158(4):1466-9.
(UI: 97445856)
Abstract: PURPOSE: We attempt to provide insight into the historical efficacy
of cryosurgical monotherapy for prostate carcinoma through a single
institution, retrospective, long-term followup. MATERIALS AND METHODS: From
1973 to 1977, 66 men underwent cryosurgical monotherapy for prostate
carcinoma. Patient charts were reviewed to determine age, clinical stage,
tumor grade, and progression-free, overall and cause specific survival
status. RESULTS: Of 51 patients 47 to 81 years old (mean age 67.2) with
clinically localized carcinoma 11 had clinical stage B and 40 had stage C
disease. Tumor grade was well differentiated in 11 cases, moderately
differentiated in 26, poorly differentiated in 11 and undetermined in 3.
Recurrence was documented in 40 of the 51 men (78.4%) as local in 34 and
unspecified in 6. Following recurrence all patients were treated with
adjuvant therapy. All but 2 patients were followed until death with a mean
followup of 93.7 months. Of the 51 men 24 (47.1%) died of disease and 17
(33.3%) died of an unspecified cause. Kaplan-Meier analysis demonstrated
median overall progression-free survival of 34 months and median overall
survival of 75 months. Median progression-free survival by grade was 34
months for well differentiated, 36 for moderately differentiated and 14 for
poorly differentiated disease (p = 0.0288), and 57 for stage B and 30 for
stage C disease (p = 0.0377). Median overall survival by grade was 114
months for well differentiated, 80 for moderately differentiated and 82 for
poorly differentiated disease (p = 0.4437), and 60 months for stage B and
78.5 for stage C disease (p = 0.4915). CONCLUSIONS: As performed in this
series cryosurgery was poorly effective for local control of prostatic
carcinoma. Stage and grade correlated with the duration of tumor response
but not with overall survival.
3. Burton SA; Paljug WR; Kalnicki S; Werts ED.
Hypothermia-enhanced human tumor cell radiosensitivity.
Cryobiology, 1997 Aug, 35(1):70-8.
(UI: 97448361)
Abstract: Ablation of neoplastic disease by freezing has found increasing
utility as a potential therapeutic modality. To assess the effect of
cooling temperatures on cellular radiation response, an established human
cervical carcinoma cell line (HTB35) was subjected to holding temperatures
of 0, 5, or 15 degrees C for up to 24 h before irradiation. Survival was
measured by in vitro clonogenic assay of colonies containing at least 50
cells. Cooling for up to 12 h did not significantly decrease survival, but
after 24 h survival fell to 75% of control cultures grown at 37 degrees C.
X-irradiation immediately after cooling for 24 h resulted in 1.6-fold
enhanced radiosensitivity. However, the radiosensitizing effect decayed
rapidly if the cooled cells were returned to normal growth temperature for
6 h or longer before irradiation and subculture. Both temperature and
cooling duration influenced the radiation response. With 0, 5, or 15
degrees C, radiosensitivity increased after 3, 6, or 12 h, respectively,
and progressively rose with up to 24 h of cooling. By flow cytometric
analysis, no statistically significant difference was observed in the
S-phase fraction between control cells and those cooled to 0 degree C for
24 h. These data demonstrate cooling-enhanced in vitro radiation
sensitivity which is dependent upon cooling temperature, duration, and
rewarming interval before irradiation. While cell cycle redistribution does
not appear to be a factor in the increased radiosensitivity, differences in
the radiation survival curves between cooled versus normothermic cells
suggest that diminished capacity for sublethal damage repair may be a
significant influence on the changes which were observed.
4. Pingsmann A; Muller RT.
[Process and outcome quality in giant cell tumor in relation to surgical
management].
Unfallchirurg, 1997 Jul, 100(7):547-51.
Language: German.
(UI: 97430504)
Abstract: Giant-cell bone tumors display a locally aggressive growth pattern,
frequently recur if no adjuvant treatment is given, and may potentially
metastasize. By virtue of their biological behavior and typically
juxta-articular localization, giant-cell bone tumors require specific
surgical management. Thus, an intralesional tumor excision must be
supplemented by adjuvant bone cementing, possibly combined with
instillation of phenol or cryotherapy. These combined treatment modalities
assure a high-quality procedure, defined as the actual way medical care is
delivered, by promoting the quality of the outcome, defined as the effect
of a medical procedure on the patient's state of health.
5. Kozielski J; Ziora D.
[Bronchoscopic cryotherapy].
Pneumonologia i Alergologia Polska, 1997, 65(5-6):411-6.
Language: Polish.
Pub type: Journal Article; Review; Review, Tutorial.
(UI: 97437111)
1. Bejjani, G K; Donahue, D J; Selby, D; Cogen, P H; Packer, R.
Association of a suprasellar mass and intraocular retinoblastoma: A
variant of pineal trilateral retinoblastoma?
Pediatric Neurosurgery, v.25, n.5, (1996): 269-275.
Abstract:
Objective and importance: 'Trilateral retinoblastoma' designates the
association of bilateral retinoblastomas with an ectopic (non-metastatic)
intracranial primitive neuroectodermal tumor (PNET). Although the
intracranial tumor, usually located in the pineal region, is seen 2-3
years after discovery of the bilateral ocular tumors, variant
presentations do occur. The intraocular tumor can be unilateral, and the
intracranial tumor can be suprasellar, presenting before the retinal
lesions. Clinical Presentation: A 4-month-old boy presented with
irritability, vomiting and nystagmus. Head CT revealed a large calcified
sellar-suprasellar mass. Ocular examination disclosed white macular
lesions in the right fundus. He was taken to surgery where subtotal
resection of the sellar-suprasellar mass was achieved. Microscopic
examination showed a primitive, small, round, blue cell tumor consistent
with retinoblastoma. The right ocular lesions, also consistent with
retinoblastoma, were treated by cryosurgery. Conclusion: The appearance of
a suprasellar PNET can precede the appearance of retinal masses in
retinoblastoma. The literature suggests that patients with 'sellar'
trilateral retinoblastoma have characteristics that differ from patients
with a pineal region trilateral retinoblastoma: the intracranial mass more
often presents initially; it occurs at a younger age; it is predominant in
females, and is more often associated with unilateral ocular lesions.
Retinal screening of patients with suprasellar PNET and other atypically
located PNETs may disclose more cases of sellar 'trilateral
retinoblastoma' and hereditary retinoblastomas. This will have
implications on genetic counseling as siblings harboring the disease may
be diagnosed and treated at an earlier stage.
(none)